Effective palliative treatment of metastatic carcinoid tumors with intra-arterial chemotherapy/chemoembolization combined with octreotide acetate

Hajarizadeh, Homayon; Ivancev, Krassi; Mueller, Charles R.; Fletcher, William S.; Woltering, Eugene A.

doi:10.1016/0002-9610(92)90392-5

Cited by 78 publications

(21 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chemoembolization depicts arterial embolization combined with intra-arterial infusion of chemotherapy, which is thought to be more effective than embolization alone with possibly more pronounced tumour reduction [31][32][33]. We have not used this treatment because of risk for more severe side effects by the added cytotoxic agent, and the additive response of chemotherapy may be less obvious in midgut carcinoids with typical low proliferation.…”

Section: Liver Embolizationmentioning

confidence: 96%

Management of midgut carcinoids

Åkerström

Hellman

Hessman

et al. 2005

Journal of Surgical Oncology

View full text Add to dashboard Cite

Midgut carcinoids developing in the small intestine represent the most common cause of the carcinoid syndrome, with severe symptoms of flush, diarrhoea, and fibrotic valvular heart disease. The tumours may be histologically identified with specific chromogranin A or synaptophysine immunostainings, and by serotonin reactivity, which supports a midgut origin. Urinary 5-HIAA excretion and serum chromogranin A measurements are used as biochemical tumour markers for clinical diagnosis, and as important monitors of treatment effects and prognostic predictors. The midgut carcinoids have typically slow proliferation and extended disease course, and surgical treatment has become increasingly important for their management. Surgery should aim to remove primary tumours and mesenteric metastases, which may cause long-term abdominal complications, by typical fibrotic intestinal entrapment and small bowel ischaemia due to encasement of mesenteric vessels. Attempts should also be made to surgically remove or ablate liver metastases, since this may significantly contribute to palliation of the carcinoid syndrome. In patients with this syndrome surgery is combined with continuous biotherapy with long-acting somatostatin analogues and interferon, which may alleviate symptoms and cause stable disease with slow progression. Favourable survival and life-quality can be expected with this treatment also in patients with advanced midgut carcinoids.

show abstract

Section: Liver Embolizationmentioning

confidence: 96%

Management of midgut carcinoids

Åkerström

Hellman

Hessman

et al. 2005

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…Dabei lag diese nach der TACE zwischen 48 und 83% [37,45,46], bei einer medianer Überlebenszeit von 24-40 Monaten [44,47]. Loewe et al [1] veröffentlichen Daten von Patienten mit Lebermetastasen eines neuroendokrinen Karzinoms, die mittels Chemoembolisation (TACE) behandelt wurden, bei der Cyanoakrylate und Lipiodol benutzt wurden.…”

Section: Disclosureunclassified

Regionale interventionelle Behandlungsverfahren von Lebermetastasen neuroendokriner Tumoren: Embolisation (TAE), Chemoembolisation (TACE) und selektive interne Radiotherapie (SIRT)

et al. 2010

View full text Add to dashboard Cite

Vorstellung technischer Grundlagen, klinischer Einschlusskriterien und der Ergebnisse sequenzieller vaskulärer Therapieverfahren wie transarterielle Embolisation (TAE), transarterielle Chemoembolisation (TACE) und selektive interne Radiotherapie (SIRT) in der Behandlung von Lebermetastasen neuroendokriner Tumoren im Rahmen des interdisziplinären Therapiemanagements. Die Indikation für die lokoregionale vaskuläre, minimalinvasive Therapie stellen in der Regel multiple Lebermetastasen dar, aufgrund ihrer starken Hypervaskularisation und der hiermit verbundenen Vorteile eines transarteriellen Verfahrens mit Embolisation. Die Ergebnisse der TAE zeigen Ansprechraten von 40 bis 54% bei einer mittleren Überlebenszeit von 33,8 Monaten. Für die TACE sind die dokumentierten Daten mit einer Ansprechrate von 23 bis 80% und einer medianen Überlebenszeit von ca. 40 Monaten unwesentlich besser. Für die SIRT liegen die mittleren Überlebenszeiten zwischen 22 und 29,4 Monaten. Regionale interventionelle Behandlungsverfahren der Lebermetastasen neuroendokriner Tumoren erlauben eine Optimierung der lokalen Kontrollrate und führen zur Minderung der Krankheitssymptomatik sowie zur Erhöhung der Überlebensraten bei möglichst höherer Lebensqualität.

show abstract

“…Furthermore, the hepatic metastases are angiographically hypervascular, extrahepatic metastases are unusual, and systemic chemotherapy is often ineffective. All of these characteristics have led investigators to attempt both palliative and definitive treatment with chemoembolization [42,80,[85][86][87][88][89][90][91][92][93][94][95].…”

Section: Neuroendocrine Metastasesmentioning

confidence: 99%

Chemoembolization in the Management of Liver Tumors

Stuart

2003

The Oncologist

View full text Add to dashboard Cite

The dual vascular supply of the liver affords a unique opportunity to explore intraarterial therapies for hepatic malignancies. Chemoembolization is a well-established technique combining intra-arterial chemotherapy with delivery of embolic agents in order to achieve an antitumor effect due to a high local concentration and prolonged dwell time of the drug, along with select ischemia. Many tumors, such as hepatocellular carcinoma, colorectal cancer, and neuroendocrine tumors, cause symptoms and death by local growth and destruction of the liver.While there are other methods capable of controlling small or isolated hepatic neoplasms, none are suitable for the majority of these patients. Chemoembolization can produce significant results in terms of tumor shrinkage in many of these patients, and there are studies to suggest a survival advantage in hepatocellular carcinoma. Toxicity, however, may be substantial, and patient selection is crucial in order to achieve the optimal benefit of this powerful technique for individual populations. The Oncologist 2003;8:425-437 The Oncologist 2003;8:425-437 www.TheOncologist.com

show abstract

Effective palliative treatment of metastatic carcinoid tumors with intra-arterial chemotherapy/chemoembolization combined with octreotide acetate

Cited by 78 publications

References 14 publications

Management of midgut carcinoids

Management of midgut carcinoids

Regionale interventionelle Behandlungsverfahren von Lebermetastasen neuroendokriner Tumoren: Embolisation (TAE), Chemoembolisation (TACE) und selektive interne Radiotherapie (SIRT)

Chemoembolization in the Management of Liver Tumors

Contact Info

Product

Resources

About